Crescita Therapeutics Inc (CTX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Crescita Therapeutics Inc (CTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013134
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Crescita Therapeutics Inc (Crescita Therapeutics) develops products for the treatment of skin diseases and their symptoms. The company’s product portfolio includes over-the-counter and prescription products such as topical creams. It offers pliaglis, a local anesthetic cream for superficial dermatological and cosmetic procedures. Crescita Therapeutics along with Ferndale Laboratories, Inc. develops Mical (1) and Mical (2) for the therapeutic areas of psoriasis and dermatological skin treatment, respectively. Mical (1) is in Phase 1 clinical trials and and Mical (2) is in preclinical stage of development. The company develops products using drug delivery platform that include multiplexed molecular penetration enhancers (MMPE) and DuraPeel. Crescita Therapeutics is headquartered in Mississauga, Ontario, Canada.

Crescita Therapeutics Inc (CTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 10
Licensing Agreements 11
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 11
Dermatological Contract Research Company Enters into Licensing Agreement with Crescita Therapeutics 12
Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 13
Debt Offering 14
Crescita Therapeutics Raises USD0.7 Million in Private Placement of 9% Convertible Debenture 14
Asset Transactions 15
Crescita Therapeutics Divests Manufacturing Facility in Germany 15
Acquisition 16
Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 16
Crescita Therapeutics Acquires Intega Skin Sciences for USD7.6 Million 17
Crescita Therapeutics Inc – Key Competitors 18
Crescita Therapeutics Inc – Key Employees 19
Crescita Therapeutics Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Nov 10, 2017: Crescita Therapeutics Announces 2017 Third Quarter Results and Appoints New CFO 21
Aug 14, 2017: Crescita Therapeutics Announces Profitable 2017 Second Quarter Results 23
May 15, 2017: Crescita Therapeutics Announces 2017 First Quarter Results 25
Mar 30, 2017: Crescita Therapeutics Announces 2016 Fourth Quarter and Year-End Results 27
Nov 14, 2016: Crescita Therapeutics Announces 2016 Third Quarter Results 29
Jul 27, 2016: Crescita Therapeutics Announces 2016 Second Quarter Results 30
May 10, 2016: Crescita Therapeutics Announces 2016 First Quarter Results 32
Corporate Communications 34
Apr 12, 2017: Crescita Therapeutics Announces the Appointment of a New President 34
Feb 10, 2017: Crescita Therapeutics Announces Management and Board Changes 35
Nov 03, 2016: Crescita Appoints Dan Chicoine as Interim CEO 36
Sep 29, 2016: Crescita Therapeutics Announces Changes to the Board of Directors 37
Product News 38
Jan 26, 2017: Crescita Therapeutics Announces Launch of ISDIN Product Line at Brunet Pharmacy 38
Other Significant Developments 39
Mar 07, 2016: Crescita Therapeutics Provides Corporate Update 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Crescita Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 10
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 11
Dermatological Contract Research Company Enters into Licensing Agreement with Crescita Therapeutics 12
Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 13
Crescita Therapeutics Raises USD0.7 Million in Private Placement of 9% Convertible Debenture 14
Crescita Therapeutics Divests Manufacturing Facility in Germany 15
Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 16
Crescita Therapeutics Acquires Intega Skin Sciences for USD7.6 Million 17
Crescita Therapeutics Inc, Key Competitors 18
Crescita Therapeutics Inc, Key Employees 19
Crescita Therapeutics Inc, Subsidiaries 20

★海外企業調査レポート[Crescita Therapeutics Inc (CTX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Century Insurance Company Limited:企業の戦略・SWOT・財務情報
    Century Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary Century Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Saia Inc (SAIA):企業の財務・戦略的SWOT分析
    Saia Inc (SAIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Hadera Paper Ltd.:企業の戦略・SWOT・財務情報
    Hadera Paper Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hadera Paper Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Rigel Pharmaceuticals Inc (RIGL):製薬・医療:M&Aディール及び事業提携情報
    Summary Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease me …
  • London Stock Exchange Group Plc:企業のM&A・事業提携・投資動向
    London Stock Exchange Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's London Stock Exchange Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Essar Power Limited:企業の発電所・SWOT分析2018
    Essar Power Limited - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Ultra Electronics Holdings Plc:企業の戦略・SWOT・財務情報
    Ultra Electronics Holdings Plc - Strategy, SWOT and Corporate Finance Report Summary Ultra Electronics Holdings Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • VWR International LLC:医療機器:M&Aディール及び事業提携情報
    Summary VWR International LLC (VWR), a subsidiary of Avantor Performance Materials Inc, is a provider of product and service solutions to laboratory and production companies. The company offers products such as adhesive dispensers, adhesive labels, adhesive slides, agarose and acrylamide, air freshe …
  • Telecom Plus plc (TEP):企業の財務・戦略的SWOT分析
    Telecom Plus plc (TEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • DHL International GmbH:企業の戦略的SWOT分析
    DHL International GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • GFI Informatique:企業の戦略・SWOT・財務情報
    GFI Informatique - Strategy, SWOT and Corporate Finance Report Summary GFI Informatique - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Societe Des Bains De Mer Sa:企業の戦略・SWOT・財務分析
    Societe Des Bains De Mer Sa - Strategy, SWOT and Corporate Finance Report Summary Societe Des Bains De Mer Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Crisil Ltd (CRISIL):企業の財務・戦略的SWOT分析
    Summary Crisil Ltd (Crisil), a subsidiary of S&P Global Inc is a financial service provider that offers risk management services. The company provides ratings, research and risk and policy advisory services. It offers services such as credit ratings, business school gradings, real estate star rating …
  • Tasly Pharmaceutical Group Co Ltd (600535):企業の財務・戦略的SWOT分析
    Tasly Pharmaceutical Group Co Ltd (600535) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • United Technologies Corporation:企業の戦略・SWOT・財務情報
    United Technologies Corporation - Strategy, SWOT and Corporate Finance Report Summary United Technologies Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Celulose Nipo-Brasileira SA:企業の戦略的SWOT分析
    Celulose Nipo-Brasileira SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Adgero Biopharmaceuticals Holdings Inc-製薬・医療分野:企業M&A・提携分析
    Summary Adgero Biopharmaceuticals Holdings Inc (Adgero) is a biopharmaceutical company which advances its proprietary late stage photodynamic therapy (PDT) for the treatment of unmet clinical needs of patients with cutaneous metastatic breast cancer (CMBC) and bile duct cancer. Its PDT is a treatmen …
  • Nido Petroleum Ltd:企業の戦略的SWOT分析
    Nido Petroleum Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Shanghai Jin Jiang International Hotels (Group) Co Ltd:戦略・SWOT・企業財務分析
    Shanghai Jin Jiang International Hotels (Group) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Shanghai Jin Jiang International Hotels (Group) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • Petrel Resources Plc (PET):企業の財務・戦略的SWOT分析
    Summary Petrel Resources Plc (Petrel Resources) is an oil and gas company that provides exploration and production of crude oil and natural gas across Iraq. The company provides areas of operations such as Luhais and Subba in Southern Iraq, Tano Basin in Ghana, Porcupine Basin in Ireland, and others …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆